ABSTRACT
@#Objective To investigate the effectiveness and safety of robotic lobectomy in clinical N0 lung malignant tumor≥3 cm. Methods We retrospectively analyzed the clinical data of 182 patients with lung malignant tumor≥3 cm receiving robotic or thoracoscopic lobectomy at Shanghai Chest Hospital in 2019. The patients were divided into a robotic surgery group (RATS group) and a thoracoscopic surgery group (VATS group). There were 39 males and 38 females with an average age of 60.55±8.59 years in the RATS group, and 51 males and 54 females with an average age of 61.58±9.30 years in the VATS group. A propensity score matching analysis was applied to compare the operative data between the two groups. Results A total of 57 patients were included in each group after the propensity score matching analysis. Patients in the RATS group had more groups of N1 lymph node dissected (2.53±0.83 groups vs. 2.07±0.88 groups, P=0.005) in comparison with the VATS group. No statistical difference was found in operation time, blood loss, postoperative hospital stay, number of N1 and N2 lymph nodes dissected, groups of N2 lymph node dissected, lymph node upstage rate or postoperative complications. The hospitalization cost of RATS was higher than that of VATS (P<0.001). Conclusion In contrast with thoracoscopic lobectomy, robotic lobectomy has similar operative safety, and a thorough N1 lymphadenectomy in patients with clinical N0 lung malignant tumor≥3 cm.
ABSTRACT
OBJECTIVE:To provide reference for reducing the occurrence of chemotherapy-induced constipation and optimizing constipation therapy.METHODS:Medical records of malignant lung tumor inpatients meeting inclusion criteria were collected from respiration department of our hospital,and then investigated and analyzed statistically in respects of patient's gender,age,constipation history,tumor types and phases,physical status score,living habit change,chemotherapy plan (including adjuvant drug),constipation occurrence,prevention and treatment,etc.The related factors of chemotherapy-induced constipation were investigated.RESULTS:A total of 135 patients were enrolled in the investigation.Of 135 patients,66 patients had constipation with incidence of 48.89％,among which 96.97％ were grade 1 and grade 2 constipation.The onset of constipation were independent from age,gender and living habit change (P＞0.05).The patients with history of constipation,advanced tumor stage,the period of treatment≥ 3 days,the use of palonosetron and combined with aprepitant had higher prevalence of constipation (P＜0.05).The clinical symptoms were improved spontaneously in 21.21％ patients,33.33％ after diet adjustment and 45.45％ by drug treatment as suppositories glycerol,lactulose;24.24％ patients used lactulose to prevent constipation at rehospitalization.CONCLUSIONS:Chemotherapy-induced constipation was commonly occurred and related to serval factors and had not got enough attention yet.The clinical pharmacists should assist the physicians to make individual chemotherapy regimen as well as the prevention of adverse drug reactions.
ABSTRACT
Objective To explore the clinical value of lymphocyte sub-population and NK levels in patients with primary lung malignant tumor and patients with chronic obstructive pulmonary disease (COPD). Methods The percentage of CD3 +,CD4 +, CD8 +, CD19 + and NK cells were measured in 60 COPD patients and 50 primary lung malignant tumor patients and 40 normal control subjects using alkaline phosphatase antialkaline phosphatase (APAAP) assay, and CD4 +/CD8 + ratio was calculated. Results The levels of CD3 +,CD4 +,CD4 +/CD8 + and CD19 + cells were significantly lower in the patients with primary lung malignant tumor or COPD than those in the normal control subjects, which CD8 level was significantly higher (P0.05). No difference in the levels of CD3 +, CD4 + and CD8 + cells was found between the primary lung malignant tumor and COPD patients, but NK and CD19 + cells levels had significant difference(P